A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.
Prednisone was granted FDA approval on 21 February 1955.
Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.
Beijing Children's Hospital, Beijing, Beijing, China
Investigational Site Number 8400009, Stamford, Connecticut, United States
Investigational Site Number 0320001, Buenos Aires, Argentina
Investigational Site Number 6430001, Moscow, Russian Federation
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Augusta University Georgia Cancer Center, Augusta, Georgia, United States
Hopital Charles-LeMoyne, Greenfield Park, Quebec, Canada
University Multiprofile Hospital for Active Treatment Saint Ivan Rilski, Sofia, Sofiya, Bulgaria
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
Loyola University Medical Center, Maywood, Illinois, United States
Jefferson University Hospitals, Philadelphia, Pennsylvania, United States
Montefiore Medical Center, Bronx, New York, United States
Shanghai Xinhua Hospital affliated to Shanghai Jiao Tong University, School of Medicine, Shanghai, Shanghai, China
Ospedale San Raffaele, Milan, Italy
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.